BEGIN:VCALENDAR PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN VERSION:2.0 BEGIN:VEVENT DESCRIPTION:SMi Group Introduces the 4th Annual Injectable Drug Delivery C onference 2022\n\n11th May to 12th May 2022\,\n\nLondon\, United Kingdom\ n\nwww.injectable-drug-delivery.com/\n\nDelivery Innovations in Formulati on and Device Design for Enhanced Subcutaneous \n\nAs Part of Europe’s le ading Injectable conference series\, we will assess innovations in drug p roduct formulation and biologics\, \;new technologies \;in device design and the use of long-release injectable compounds.\n\nThere is a r ising demand for vaccines\, insulin\, \;and many modern medicines use d to treat cancer and other chronic diseases. As biologics are mainly adm inistered through the injectable route\, the significant growth in the bi ologics market is expected to drive the injectable drug delivery and pref illed syringe market in the coming years. The injectable drug delivery ma rket is expected to rise at a compound annual growth rate of 12.9% reachi ng £915 billion by 2027.\n\nThis year’s event will highlight the signific ance of sustainability within the injectable drug delivery industry\, whi lst also providing regulatory insight on the changes that have occurred. There will be an additional focus on the impact that covid has had on the success within this industry over the past year. The conference will als o highlight successes within the industry and the formulation challenges of long-lasting\, highly viscous and high-volume drug delivery. \; ww w.injectable-drug-delivery.com/\n\n \;\n\nThe benefits of attending:\ n\n\nDiscover \;the new technologies and latest injectable devices be ing used within the industry \;\nDevelop \;your understanding of high-volume and long-acting injectable compounds \;\nExplore \;th e sustainable possibilities that can be adapted within the industry for a green future\nDelve \;into the world of biologics and biosimilars an d what these mean for the injectable drug market \;\nNetwork \;wi th key industry leaders and discover the leading companies within the inj ectables space\n\nWho should attend:\n\nExecutives\, Directors\, VPs\, He ads\, Principals\, Managers\, Scientists\, Researchers of:\n\n\nAutoinjec tors\nWearables\nDevice Engineering\nHuman Factors\nCMC\nInjectables\nSte rile Manufacturing\nPackaging\nRegulatory Affairs\n\n \;\n\nwww.injec table-drug-delivery.com/\n\n \;\n\nFeatured Speakers:\n\n\nAlexander Zuern\, Device testing manager\, Novartis International AG\nAndrew Warrin gton\, Project Leader &\; Patient Advocate\, Novartis\nBenjamin Werner \, Scientist\, Boehringer Ingelheim Pharma GmbH &\; Co. KG\nBjorg K Hu nter\, Regulatory Manager\, Devices\, GSK\nBlake Green\, Senior Manager R egulatory Affairs\, Amgen\nCamille Dagallier\, Formulation and Drug Proce ss Development Senior Scientist\, Sanofi\nChristopher Muenzer\, Senior De vice Technology Manager\, Novartis\nJoel Richard\, Head of Technical & \; Pharmaceutical Operations\, MedinCell\nMark Palmer\, Scientific Leader \, Biopharm Device Engineering\, GSK\nRebecca Moses\, Director\, Core Hum an Factors Inc.\nRupal Nguyen\, Principal Engineer\, Allergan\nStefania R agone\, Pharmaceutical Assessor\, Medicines &\; Healthcare Products Re gulatory Agency (MHRA)\nTina Arien\, Principal Scientist\, Janssen Pharma ceutica\nVikas Jaitely\, Director\, Global Regulatory Affairs Transitiona l Medicine and Devices\, Merck\n\n \;\n\nPast attendees have included \n\nAdvanz Pharma\; Amgen\; AstraZeneca\; BD - Becton Dickinson\; Bd Medi cal-Pharmaceutical Systems\; BD Technologies and Innovation\; Becton Dick inson\; Boehringer Ingelheim GmbH &\; Co. KG\; Boehringer Ingelheim Ph arma GmbH &\; Co. KG\; BSI Group\; Chugai Pharmaceutical CO. LTD.\; Co ngenius\; Core Human Factors\; F Hoffmann -La Roche Inc\; GlaxoSmithKline \; Glenmark Pharmaceuticals Inc.\; GSK\; Haselmeierá\; Haughton Design Lt d\; Ipsen Biopharm Limited\; Janssen Pharmaceutica\; Janssen Pharmaceutic a NV\; Legacy Allergan/AbbVie\; LEO Pharma A/S\; MedinCell\; Merck\; Merc k Connected Health &\; Devices\; MHRA\; Micropore Technologies Ltd\; N ovartis / DD&\;C\; Novartis International AG\; Novo Nordisk Pharma\; O wen Mumford\; Pfizer UK Limited\; Raumedic AG\; Roche\; SABIC\; Sabic SHP P\; Sandoz – A Novartis Company\; Sanofi\; Sanofi SWI\; Team Consulting\; Teva Pharamceuticals\; UCB\; Vetter Pharma-Fertigung GmbH &\; Co. KG\ ; Zealand Pharma A/S\n\n \;\n\nwww.injectable-drug-delivery.com/\n\n& nbsp\;\n\nAdditional Contact Info:\n\nT: +44 (0)20 7827 6088\n\nE: rjones @smi-online.co.uk\n\nLinkedIn: @SMi Pharma\n\nTwitter: @SMiPharm #SMiInje ctables\n\n \;\n\nAbout SMi Group:\n\nEstablished since 1993\, the SM i Group is a global event-production company that specializes in Business -to-Business Conferences\, Workshops\, Masterclasses and online Communiti es. We create and deliver events in the Defence\, Security\, Energy\, Uti lities\, Finance and Pharmaceutical industries. We pride ourselves on hav ing access to the world’s most forward-thinking opinion leaders and visio naries\, allowing us to bring our communities together to Learn\, Engage\ , Share and Network. More information can be found at http://www.smi-onli ne.co.uk\n DTEND:20220512T180000 DTSTAMP:20260512T220023Z DTSTART:20220511T080000 LOCATION:Holiday Inn London - Kensington High St.\, an IHG Hotel\, Wrights Lane\, London\, Greater London\, W8 5SP\, SEQUENCE:0 SUMMARY:SMi Group Introduces the 4th Annual Injectable Drug Delivery Confe rence 2022\n11th May to 12th May 2022\,\nLondon\, United Kingdom\nwww.inj ectable-dr... UID:e86fa040-731f-4c3c-ba73-24bff2af4ca2 END:VEVENT END:VCALENDAR